These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 1622119)

  • 1. Interaction of cytotoxic agents: a rule-based system for computer-assisted cell survival analysis.
    Gentile FP; Chiatti L; Mauro F; Briganti G; Floridi A; Benassi M
    Anticancer Res; 1992; 12(3):637-43. PubMed ID: 1622119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction index and different methods for determining drug interaction in combination therapy.
    Lee JJ; Kong M; Ayers GD; Lotan R
    J Biopharm Stat; 2007; 17(3):461-80. PubMed ID: 17479394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
    Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
    Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro.
    Ning SC; Hahn GM
    Cancer Res; 1990 Dec; 50(24):7867-70. PubMed ID: 2253227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating response to antineoplastic drug combinations in tissue culture models.
    Reynolds CP; Maurer BJ
    Methods Mol Med; 2005; 110():173-83. PubMed ID: 15901935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression.
    Notarbartolo M; Poma P; Perri D; Dusonchet L; Cervello M; D'Alessandro N
    Cancer Lett; 2005 Jun; 224(1):53-65. PubMed ID: 15911101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine.
    Greco WR; Park HS; Rustum YM
    Cancer Res; 1990 Sep; 50(17):5318-27. PubMed ID: 2386940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.
    Wadler S; Schwartz EL
    Cancer Res; 1990 Jun; 50(12):3473-86. PubMed ID: 1692761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
    Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
    Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
    Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
    Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation by squalene of the cytotoxicity of anticancer agents against cultured mammalian cells and murine tumor.
    Nakagawa M; Yamaguchi T; Fukawa H; Ogata J; Komiyama S; Akiyama S; Kuwano M
    Jpn J Cancer Res; 1985 Apr; 76(4):315-20. PubMed ID: 2408954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
    Meurette O; Lefeuvre-Orfila L; Rebillard A; Lagadic-Gossmann D; Dimanche-Boitrel MT
    Clin Cancer Res; 2005 Apr; 11(8):3075-83. PubMed ID: 15837763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines.
    Peters RH; Jollow DJ; Stuart RK
    Cancer Res; 1991 May; 51(10):2536-41. PubMed ID: 2021933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
    Vadi H; Drewinko B
    Cancer Res; 1986 Mar; 46(3):1105-9. PubMed ID: 3080232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.